Upcoming biologic agents for the treatment of rheumatic diseases

被引：45

作者：

Shanahan, JC ^{[1
]}

Moreland, LW ^{[1
]}

Carter, RH ^{[1
]}

机构：

[1] Univ Alabama Birmingham, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA

来源：

CURRENT OPINION IN RHEUMATOLOGY | 2003年 / 15卷 / 03期

关键词：

D O I：

10.1097/00002281-200305000-00009

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The development of biologic agents has provided rheumatologists with a variety of new and effective treatment options. The success of early biologics, especially etanercept and infliximab for the treatment of rheumatoid arthritis, has spurred research into novel targets for the management of systemic inflammatory and autoimmune diseases. In addition, existing biologics approved for use in other diseases, such as rituximab, are now under study for the treatment of new indications. This article reviews ongoing research on the treatment of rheumatic diseases with new and existing biologic agents.

引用

页码：226 / 236

页数：11

共 126 条

[1] CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris [J].

Abrams, JR ;

Lebwohl, MG ;

Guzzo, CA ;

Jegasothy, BV ;

Goldfarb, MT ;

Goffe, BS ;

Menter, A ;

Lowe, NJ ;

Krueger, G ;

Brown, MJ ;

Weiner, RS ;

Birkhofer, MJ ;

Warner, GL ;

Berry, KK ;

Linsley, PS ;

Krueger, JG ;

Ochs, HD ;

Kelley, SL ;

Kang, SW .

JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (09) :1243-1252

[2] Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells [J].

Abrams, JR ;

Kelley, SL ;

Hayes, E ;

Kikuchi, T ;

Brown, MJ ;

Kang, SW ;

Lebwohl, MG ;

Guzzo, CA ;

Jegasothy, BV ;

Linsley, PS ;

Krueger, JG .

JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (05) :681-693

[3] Chemokines as novel therapeutic targets in inflammatory diseases [J].

Ajuebor, MN ;

Swain, MG ;

Perretti, M .

BIOCHEMICAL PHARMACOLOGY, 2002, 63 (07) :1191-1196

[4] Interferon alfa-2a in the treatment of Behcet disease - A randomized placebo-controlled and double-blind study [J].

Alpsoy, E ;

Durusoy, C ;

Yilmaz, E ;

Ozgurel, Y ;

Ermis, O ;

Yazar, S ;

Basaran, E .

ARCHIVES OF DERMATOLOGY, 2002, 138 (04) :467-471

[5] Therapeutic intervention with inhibitors of co-stimulatory pathways in autoimmune disease [J].

Aruffo, A ;

Hollenbaugh, D .

CURRENT OPINION IN IMMUNOLOGY, 2001, 13 (06) :683-686

[6] Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab) [J].

Arzoo, K ;

Sadeghi, S ;

Liebman, HA .

ANNALS OF THE RHEUMATIC DISEASES, 2002, 61 (10) :922-924

[7] IL-10 is a key cytokine in psoriasis -: Proof of principle by IL-10 therapy:: A new therapeutic approach [J].

Asadullah, K ;

Sterry, W ;

Stephanek, K ;

Jasulaitis, D ;

Leupold, M ;

Audring, H ;

Volk, HD ;

Döcke, WD .

JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (04) :783-794

[8] Adult onset Still's disease: response to Enbrel [J].

Asherson, RA ;

Pascoe, L .

ANNALS OF THE RHEUMATIC DISEASES, 2002, 61 (09) :859-860

[9] Signaling through OX40 (CD134) breaks peripheral T-cell tolerance [J].

Bansal-Pakala, P ;

Jember, AGH ;

Croft, M .

NATURE MEDICINE, 2001, 7 (08) :907-912

[10] (E)-2(R)-[1(S)-(Hydroxycarbamoyl)-4-phenyl-3-butenyl]-2′-isobutyl-2′-(methanesulfonyl)-4-methylvalerohydrazide (Ro 32-7315), a selective and orally active inhibitor of tumor necrosis factor-α convertase [J].

Beck, G ;

Bottomley, G ;

Bradshaw, D ;

Brewster, M ;

Broadhurst, M ;

Devos, R ;

Hill, C ;

Johnson, W ;

Kim, HJ ;

Kirtland, S ;

Kneer, J ;

Lad, N ;

Mackenzie, R ;

Martin, R ;

Nixon, J ;

Price, G ;

Rodwell, A ;

Rose, F ;

Tang, JP ;

Walter, DS ;

Wilson, K ;

Worth, E .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 302 (01) :390-396

← 1 2 3 4 5 6 7 8 9 10 →